Business Context and Reporting Period
This Form 6-K filing by Alpha Tau Medical Ltd. covers the month of June 2025, specifically reporting on the Annual General Meeting of Shareholders held on June 17, 2025, in Jerusalem, Israel.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance actions and shareholder approvals rather than financial performance data.
Material Changes and Corporate Actions
- Board Elections: Shareholders re-elected Alan Adler and S. Morry Blumenfeld and elected Nadav Kidron as Class I directors, serving until the 2028 Annual General Meeting.
- Warrant Issuance: Approved the issuance of warrants under a strategic services agreement with Oramed Ltd. (dated April 24, 2025):
- 2,390,000 warrants with an exercise price of $3.90 per share.
- 847,000 warrants with an exercise price of $3.474 per share.
- Auditor Re-appointment: Re-appointed Kost, Forer, Gabbay & Kasierer (Ernst & Young Global) as the independent registered public accounting firm for the year ending December 31, 2025.
- Compensation: Approved and ratified an amendment to the Non-Employee Director Compensation Package.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, future outlook, management commentary on operations, specific risks, or contingencies. The document serves as a formal record of shareholder resolutions.
Investor Verification Checklist
- Verify the terms and dilution impact of the 3,237,000 total warrants issued to Oramed Ltd.
- Review the specific details of the amended Non-Employee Director Compensation Package.
- Confirm the strategic implications of the services agreement with Oramed Ltd. referenced in the warrant approval.
- Check the Proxy Statement (Exhibit 99.1 filed May 13, 2025) for detailed voting results and director biographies.